Kadcyla Manufacturing Review Was A Production In Itself
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The complex manufacturing required by Genentech’s antibody-drug conjugate trastuzumab emtansine pushed FDA’s review two months past the agency’s internal action timetable, required four review teams from three CDER offices and produced a veritable blizzard of information requests. But is that level of intensity sustainable as the expanding ADC pipeline matures?
You may also be interested in...
Genentech’s Cancer Product Line Expands, As Do Its Post-Market Manufacturing Obligations
Genentech appears to be having significant manufacturing problems for some of its new cancer therapies. FDA hasn’t taken enforcement action yet, but the agency has delayed two approvals and tied them to post-market requirements to address QC issues.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.